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Available online 6 March 2017Sudden cardiac death (SCD) is defined as “a non-traumatic, unexpected, fatal event occurring within one hour of
the onset of symptoms in an apparently healthy subject”, and it causes a fifth of all deaths worldwide. It often
occurs in individuals not previously known with cardiac disease, which makes prevention challenging. The
mechanism underlying SCD is thought to be a trigger (e.g. ischemia) acting upon a substrate (e.g. scar), causing
a lethal arrhythmia. Primary prevention refers to patients at high risk of SCD and secondary prevention to those
who have had an aborted episode of SCD. Insertion of an implantable, cardioverter-defibrillator (ICD) is the most
effective approach to primary prevention; currently ICD candidate selection is based on a left ventricular ejection
fraction (LVEF) ≤35%. The LVEF is neither sensitive nor specific in identifying individuals who will benefit from
ICD therapy, and therefore alternative strategies are required. The present review article summarizes the evi-
dence on various non-imaging (e.g. microvolt T-wave alternans, signal-averaged ECG, QRS fragmentation and
measures of autonomic function) and imaging (echocardiography, cardiacmagnetic resonance and radionuclide)
modalities showing incremental value over LVEF to identify the patients who will benefit from an ICD.







Sudden cardiac death (SCD) is defined as “a non-traumatic, unex-
pected, fatal event occurring within one hour of the onset of symptoms
in an apparently healthy subject” in the guideline on management of
patients with ventricular arrhythmias (VA) and the prevention of SCD
of the European Society of Cardiology [1]. An unwitnessed death can
still be considered a SCD if the individual in questionwas in good health
24 h before the event [1]. SCD accounts for N4 million global deaths per
year, which translates into onefifth of all recorded deaths [1]. About half
of SCD's occur in individuals who are not known to have underlying
heart disease before the fatal event, thus presenting a significant
challenge to effective prevention [1].2. SCD: causes, mechanisms and prevention
The most common cause of SCD is coronary artery disease, which
accounts for up to 50% of SCD in white males. Other causes of SCD are:
cardiomyopathies, cardiac hypertrophy, valvulopathies, myocarditis
and primary electrical disorders.
The underlying mechanism of SCD is currently understood as a
trigger which acts on a substrate, thereby causing a lethal arrhythmia
(ventricular tachycardia or ventricular fibrillation) and subsequentgy, Leiden University Medical
land Ltd. This is an open access articlhemodynamic instability. A typical example of such an interaction is
myocardial ischemia (trigger) interacting with post-infarct myocardial
scar (substrate) in the so-called peri-infarct zone. This zone represents
a transition between the infarct core and healthymyocardium, and con-
tains scar tissue which is interspersed with normal cardiomyocytes.
Slow conduction of electrical impulses occur in the peri-infarct zone,
allowing the establishment of re-entry circuits and arrhythmias.
Prevention of SCD is twofold: primary, i.e. in patients deemed to be
at high risk of SCD, or secondary, i.e. who have had an episode of SCD
aborted spontaneously or by resuscitation efforts. The most effective
strategy for both primary and secondary prevention of SCD is the
implantable, cardioverter-defibrillator (ICD). Evidence for the use of
ICD in primary prevention arose from the Multicenter Automatic
Defibrillator Implantation Trial (MADIT II) and the Sudden Cardiac
Death in Heart Failure Trial (SCD-HeFT) [2,3]. The rate of SCD was
decreased by N30% in patients with a myocardial infarction and a left
ventricular ejection fraction (LVEF) of ≤30% in MADIT II [2]. Similarly,
all-cause mortality was reduced by N20% in heart failure patients with
LVEF ≤35% in SCD-HeFT [3].
3. Selection of ICD candidates: current practise
The decision to implant an ICD for primary prevention is currently
based primarily on the LVEF. An LVEF ≤35% is a class IA indication for
ICD according to current European Society of Cardiology guidelines
[1]. An exception to this recommendation is the patients with LVEF
≤35% within the first 6 weeks after myocardial infarction. This is based
on the results of the Defibrillator in Acute Myocardial Infarction Triale under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Summary of studies reporting the characteristics of the patients with appropriate ICD therapy.
Study Year published No. of patients LVEF (%)a Duration of follow-up Appropriate therapy (%)
Sabbag et al. [5] 2015 2349 b40% in 66% of patients 2.5 years 2.6 (shock)
Weeke et al. [6] 2013 1609 25 (20−30) Mean 1.9 ± 1.3 years 13.4 (shock & ATP)
7.8 (shock)
MacFadden et al. [7] 2012 3822 29 ± 11 (women)
31 ± 14 (men)
1 year 15.3 (women)
21 (men) (shock & ATP)
Huikuri et al. [8] 2009 312 30 ± 6 2 years 8 (VT/VF on loop recorder)
Chow et al. [9] 2008 575 24 ± 4.8 Mean 2.1 ± 0.9 years 11.1 (shock & ATP)
Bardy et al. [3] 2005 829 24 (19–30) Median 3.8 years 21 (shock)
Moss et al. [10] 2004 720 23 ± 5 3 years 35 (shock & ATP)
ATP: antitachycardia pacing; LVEF: left ventricular ejection fraction; VF: ventricular tachycardia, VT: ventricular fibrillation.
a LVEF is presented as mean ± standard deviation or median and interquartile range.
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post-infarction failed to reduce all-cause mortality [4].
However, LVEF ≤35% may not be sensitive enough to select ICD
candidates for primary prevention. In the Oregon Sudden Unexpected
Death Study (2093 patients with SCD and 448 with echocardiographic
data) only 20.5% of patients had LVEF ≤35%. Furthermore, a number of
studies have demonstrated that appropriate therapy occurs in less
than a third of ICD recipients with LVEF ≤35% (while still exposing
them to potential complications of the device) (Table 1) [3,5–10].
Accordingly, relying on LVEF alone for guiding selection of ICD candi-
dates for primary prevention, may not be the ideal strategy.
4. Patient selection based on non-imaging based techniques
Investigation of non-imaging approaches for SCD risk-stratification
has been directed mainly at electrophysiological parameters, e.g.Fig. 1. Imaging modalities to assess the risk of ventricular arrhythmias and sudden cardiac dea
strain (B) and mechanical dispersion (C) can be assessed. Ischemic heart failure patient with
segments coded in blue (meaning lengthening) and shades of red (meaning better shorte
posterolateral regions (C). Thinned, inferoseptal and inferior, basal segments post-infarct, d
(CMR) (D, arrow). Midwall-fibrosis of the interventricular septum in a patient with dilated
18F–fluorodeoxyglucose on a fused, positron emission tomography and computed tomog
sarcoidosis (F, arrow).microvolt T-wave alternans (MTWA), signal-averaged ECG (SAECG),
QRS fragmentation and measures of autonomic function (e.g. heart
rate variability (HRV)).
MWTA is the consequence of abnormal handling of intracellular
calcium and has been associated with increased risk of SCD in a study
of 768 patients with ischemic cardiomyopathy (hazard ratio 2.29;
p = 0.049) [11]. Late potentials, recorded in the terminal QRS complex,
are the basis for an abnormal SAECG. VA and death occurred in 28%
and 17% (p = 0.0001) of patients with an abnormal and normal
SAECG, respectively, after 5 years of follow-up in 1925 patients with
coronary artery disease [12]. Conversely, no clear link was established
with VA or SCD in 313 patients referred for an electrophysiology
study [13]. QRS fragmentation can be measured non-invasively with
magnetocardiography, which records cardiac electromagnetic activity
with detectors placed close to the thoracic wall. QRS fragmentation
was significantly increased in patients with VA, compared to thoseth. With speckle-tracking echocardiography (A), left ventricular (LV) global longitudinal
dilated left ventricle (A) and significantly impaired LV global longitudinal strain, with LV
ning) (B), and large mechanical dispersion with the latest activated segments in the
elineated by late gadolinium enhancement (LGE) cardiac magnetic resonance imaging
cardiomyopathy, indicated by LGE-CMR imaging (E, arrow). Increased apical uptake of
raphy scan, indicating the location of cardiac inflammatory activity in a patient with
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infarct patients [14].
5. Patient selection based on novel imaging techniques
Strain echocardiography, late gadolinium contrast enhanced (LGE)
cardiac magnetic resonance (CMR) and nuclear imaging techniques
have provided measures with incremental value over LVEF to iden-
tify the patients who may benefit from an ICD. These imaging mo-
dalities permit visualization of both triggers (e.g. myocardial ischemia)
and substrates (e.g. scar) for SCD in ischemic and non-ischemic
cardiomyopathy.
With speckle tracking echocardiography, the active deformation
(strain) of the myocardium can be assessed as a measure of LV systolic
function and as an indirect reflector of myocardial fibrosis/scar. Global
longitudinal strain (GLS) has been independently associated with
SCD, appropriate ICD therapy and VA in ischemic cardiomyopathy
patients (Fig. 1A-B), cardiac systemic sclerosis and in repaired tetralo-
gy of Fallot [15]. In patients with myocardial infarction, the value of
longitudinal strain in the peri-infarct zone predicts appropriate ICD
therapy [15]. In addition, by measuring the time to peak longitudinal
strain in 17 LV segments, LV mechanical dispersion can be assessed.
A large LV mechanical dispersion suggests the presence of slow and
heterogeneous electrical conduction of the LV myocardium (e.g. due
to areas of scar) (Fig. 1C). Each 10 ms increase in LV mechanical dis-
persion has been associated with increased risk of VA in 988 patients
after acute ST-elevation myocardial infarction (hazard ratio 1.15;
p = 0.032) [15].
The presence and burden of myocardial scar detected with LGE CMR
relates to SCD, appropriate ICD therapy andVA in patientswith ischemic
and non-ischemic cardiomyopathies (Fig. 1D-E) [16,17]. Most impor-
tantly, quantification of the peri-infarct zone area with LGE-CMR has
shown incremental prognostic value over the extent of myocardial
scar, suggesting that the peri-infarct zone reflects better the substrate
susceptible to develop VA. The size of the peri-infarct zone remains in-
dependently associated with all-cause mortality when corrected for
LVEF (hazard ratio 1.42; p = 0.002) and for scar burden (hazard ratio
1.25; p b 0.001) [18].
The use of radionuclide imaging for SCD assessment has focused on
cardiac innervation. SCD and appropriate ICD therapy is more common
in heart failure patients (ischemic and non-ischemic)with a highwash-
out rate or a decreased heart/mediastinum uptake ratio (H/M) of
Iodine-123 (123I) metaiodobenzylguanidine (MIBG), an analogue of
noradrenaline which indicates areas of myocardial denervation [19].
An H/M ratio ≥1.6 was independently associated with less SCD and VA
in heart failure patients when taking LVEF into account (hazard ratio
0.36; p = 0.006) [19].
Similarly, 123I-MIBG imaging has proven useful to identify patients
with hypertrophic cardiomyopathy and arrhythmogenic, right ven-
tricular cardiomyopathy who are at risk of VA [17]. Using the radio-
pharmaceutical carbon-11-metahydroxyephedrine, positron emission
tomography (PET) permits detection of sympathetic denervation in
ischemic heart disease, which has been associated with increased
risk for SCD. The presence of perfusion defects (rubidium-82) and in-
flammation (increased 18F-fluorodeoxyglucose (FDG) uptake) on PET
are predictive of VA in patients with cardiac sarcoidosis. Integrated
PET-computed tomography scans identify the location of cardiac inflam-
mation with 18F-FDG uptake, and can diagnose extra-cardiac disease
and thoracic lymphadenopathy (Fig. 1 F).
6. Conclusion
Although contemporary selection of ICD candidates for primary
prevention is based on an LVEF ≤35%, novel non-imaging and imaging
based strategies have demonstrated incremental value over usingLVEF in isolation. Prospective trials are required to validate the benefit
of imaging techniques in the appropriate selection of ICD candidates.
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